PubMed Health⌕ Search

Biomedical subjects

Jean-Louis Davin

Publications and source records attributed to Jean-Louis Davin.

At least 19 recordsLinked to original sources
PubMed2006

[Intravesical BCG instillations for the treatment of superficial bladder tumours in renal transplant recipients].

Superficial urothelial tumours of the bladder are more frequent and more often at higher risk of progression and recurrence in renal transplant recipients. When conservative treatment of these tumours is indicated, BCG instillations are recommended. However, immunosuppression of renal transplant recipients constitutes a classical contraindication to BCG therapy. Some authors have nevertheless used BCG instillations in renal transplant recipients. The authors reviewed the use of BCG in renal transplant recipients by studying the effects of immunosuppression on the mechanisms of action of BCG and the various clinical experiences reported in the international literature.

Adjuvants, Immunologic↗
PubMed2006

[Management of positive margins after total prostatectomy for localized prostate cancer].

Positive margins after total prostatectomy are frequently observed (10% to 40% of cases) in the everyday practice of urologists treating prostate cancer The presence of positive margins is correlated with the presence of residual tumour in about 50% of cases. It is difficult to clearly define optimal management in view of the marked heterogeneity of the published data concerning the significance and prognosis of positive margins. The objective of this review article was to analyse the various aspects of this situation and to propose practical management guidelines. This analysis was based on data of the literature derived from Medline. In practice, it is essential to more precisely define the concept of positive margins in histological terms by specifying the unifocal or multfocal nature, the total length of positive margins and their site. The decision to perform adjuvant or deferred therapy is based on these histopathological elements together with other prognostic criteria determined after total prostatectomy: pathological stage and Gleason score, tumour volume and postoperative PSA.

Humans↗
PubMed2005

[Follow-up of renal cancer. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie].

The follow-up of renal cancer is essentially based on thoracoabdominal computed tomography (CT). The duration of this follow-up and the frequency of examinations depend on the patient's level of risk. Early detection of metastases has a limited therapeutic value at the present time, apart from tumours with a good prognosis or for the management of complications. Recent publications on targeted treatments raise new hopes and may lead to a modification of follow-up guidelines.

Algorithms↗
PubMed2005

[Follow-up of urothelial tumours. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie].

The follow-up of urothelial tumours is designed to allow early detection of recurrence or progression, for which treatment is possible. Recent interesting points are: the more frequent and simpler use of the new classification into low grade and high grade, essentially applied to the management and surveillance of tumours involving the mucosa or lamina propria; and the limited place of urinary markers.

Carcinoma, Transitional Cell↗
PubMed2004

[Diagnosis and management of advanced hormone-refractory prostate cancer: results of a practice survey on 301 French urologists].

As no treatment has been demonstrated to prolong survival in hormone-refractory prostate cancer, it was interesting to define the current management of these patients. This survey was designed to identify the criteria used to define hormonal escape, to more clearly define the treatment modalities at this stage of the disease and to evaluate the various therapeutic approaches used. A self-administered questionnaire accompanied by 3 clinical cases was sent by mail to all French urologists registered with the AFU. Three hundred and one (31%) questionnaires were returned. The diagnosis of hormone-refractory cancer was based on the presence of clinical signs or elevated PSA levels in 61% of cases. 65% of urologists reported that they changed treatment as soon as symptoms appeared. The objectives of treatment were improvement of quality of life in 95% of cases and relief of symptoms in 90% of cases. The first-line treatment after hormonal escape is very predominantly (at least 90% of cases) multiple hormonal manipulations. Chemotherapy or referral of patients to an oncologist is performed by more than one third of doctors as second-line treatment (35% of cases) and in almost all cases as third-line treatment (87% of cases). Mitoxantrone-prednisone is the combination chemotherapy most frequently reported in this survey (2 out of 3 doctors). These data illustrate the application by French urologists of the current CCAFU guidelines (Oncology Committee of the French Urology Association) for hormone-refractory prostate cancer.

Androgen Antagonists↗
PubMed2004

[Urothelial tumors].

Explore the source record for details and available documents.

Carcinoma, Transitional Cell↗
PubMed2003

[Prostate cancer screening].

Prostate cancer has become the most frequent cancer and the second cause of cancer mortality in men. This public health problem is becoming increasingly important due to the increasing life expectancy. At the present time, prostate cancer will be discovered in one in every eight men during their lifetime. Prostate cancer represents 25% of all new cases of male cancers. Prostate cancer screening is designed to detect early stage, asymptomatic prostate cancer, as the patient's chances of cure are higher when the cancer is diagnosed at an early stage. The conclusions of the ANAES evaluation in 1998 did not recommend mass screening for prostate cancer. Several international prospective randomized studies based on serum PSA assay, sometimes associated with digital rectal examination, are currently underway. France is participating in the European ERSPC study (European Randomized Study of Screening for Cancer Prostate) and is organizing a national study on high-risk populations. While waiting for the final results of these studies, a recommendation needs to be proposed to inform general practitioners and specialists about optimal use of the currently available tests. Based on the conclusions of its oncology committee (composed of urologists, medical oncologists, radiotherapists, pathologists and radiologists), the Association Française d'Urologie proposes a recommendation concerning prostate cancer screening and defines its modalities, especially concerning the target population, screening tests and the information given to men before screening. The Association Française d'Urologie recommends prostate cancer screening by PSA assay (prostate specific antigen) and digital rectal examination annually between the ages of 50 and 75 years, and from the age of 45 years in men with a family or ethnic risk. If total PSA is above the normal value of the test or if digital rectal examination is abnormal, referral to a urologist is recommended. Information concerning the limits, benefits and risks of screening and the available treatment options must be given before performing these examinations.

Humans↗